Treatment of External Auditory Canal Hemangioma by Surgical Excision and Flap Reconstruction: 2 Case Reports.

Am J Case RepOct 5, 2026 (epub)
Case ReportOtolaryngology (ENT)Pathology (Anatomic & Clinical)Radiology (Diagnostic)

Qian Zhang, Wenjin Wu, Linrui Chen et al.

✦ AI-curated · Sources linked

Case in brief

Two cases of external auditory canal (EAC) hemangiomas are reported. The first case involved a 68-year-old man with a sensation of fullness in the left ear, while the second case involved a 62-year-old woman with right-ear fullness, hearing loss, and tinnitus. Imaging revealed well-defined soft-tissue masses in the EAC. Both patients underwent complete trans-canal excision with skin flap reconstruction, resulting in full symptom resolution and intact canal anatomy at 1-year follow-up.

Diagnostic / clinical pearl

EAC hemangiomas can present with symptoms such as fullness, hearing loss, and tinnitus, and imaging is crucial for diagnosis and surgical planning.

Why it matters

This case highlights the effectiveness of trans-canal excision and flap reconstruction in managing cavernous hemangiomas of the EAC, ensuring symptom resolution and preservation of canal integrity.

Source

PubMed · PMID 42832425

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.